The study provides evidence that CDRI-85/287 exerts its anti-proliferative and anti-invasive properties via preventing EGFR activation and subsequently inhibits the tumor growth by inhibiting PI-3-K/Akt and MEK/Erk pathways. Here, EGFR is linked to neoplasm.